News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Dorsavi.
RELATED STOCKHEAD STORIES
News
ASX Lunch Wrap: Geopolitics rock the boat; Narryer up 80pc on scandium and REE find
Health & Biotech
ASX Health Stocks: Optiscan reveals new breakthrough on remote pathology technology
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Local markets have made just a terrific recovery as iron ore bounces back
News
ASX Small Cap Lunch Wrap: Fear as ASX falls and a surprise AI buy emerges
News
Top 10 at 10: AI, big gold hits, and a $65m cash windfall
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX ends higher but iron’s ordinary problem isn’t going away
News
In Case You Missed It: New niobium and REE projects plus scaffold distribution deals
Health & Biotech
ASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trial
News
Top 10 at 10: All eyes are on Azure, SQM, and Gina
News
CLOSING BELL: And the Oscar for Best Performing Company in a Comedy Drama goes to…
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Memphasys plans in vivo studies in Japan, Canada; ECS sells Tassie assets
Health & Biotech
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
Health & Biotech
ASX Health Stocks: dorsaVi gets ISO certification; Actinogen to begin Phase 2 trial
Health & Biotech
